Combining BRAF inhibition with oncolytic herpes simplex virus enhances the immune-mediated antitumor therapy of BRAF-mutant thyroid cancer

Background The aggressive clinical behavior of poorly differentiated and anaplastic thyroid cancers (PDTC and ATC) has proven challenging to treat, and survival beyond a few months from diagnosis is rare. Although 30%–60% of these tumors contain mutations in the BRAF gene, inhibitors designed specif...

Descripció completa

Dades bibliogràfiques

Autors principals:	Khin Thway, Kevin J Harrington, Alan A Melcher, Eva Crespo-Rodriguez, Katharina Bergerhoff, Galabina Bozhanova, Shane Foo, Emmanuel C Patin, Harriet Whittock, Richard Buus, Syed Haider, Gareth Muirhead, Kate Newbold, Robert S Coffin, Richard G Vile, Dae Kim, Martin McLaughlin, Malin Pedersen
Format:	Artigo
Idioma:	Inglês
Publicat:	BMJ Publishing Group 2020-10-01
Col·lecció:	Journal for ImmunoTherapy of Cancer
Accés en línia:	https://jitc.bmj.com/content/8/2/e000698.full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!